Clinicopathologic features and KRAS mutation incidence of gastric carcinomas

Objectives: This study aims to determine the frequency of KRAS mutations in patients with gastric adenocarcinoma (GAC) Hatay province, and relationship this mutation some pathological clinical parameters guide diagnosis treatment planning patients. Methods: Formalin-fixed, paraffin-embedded, histologically confirmed samples were used assessment mutation. Sections taken from archive tissue each case. Real-Time Polymerase Chain Reaction (RT-PCR) system was identify codons 12 13 (exon 2) RAS gene. Mutations GLY12ALA (G12A), GLY12ASP (G12D), GLY12ARG (G12R), GLY12CYS (G12C), GLY12SER (G12S), GLY12VAL (G12V), GLY13ASP (G13D) performed. Results: The rate 2% only one substitution, G12D, detected. In case, tumor located small curvature. Since number cases low, statistical comparison could not be made between clinicopathological factors. A significant difference found differentiation WHO-2010 typing primary stage. Conclusions: We incidence 2%. also estimate that G12D may associated GAC site surgical margin. Although alone is a prognostic or predictive marker, subtype-specific analysis provide data affect diagnosis, management disease